Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
Journal of Immunopharmacology|January 1, 1984
Investigations on the age-dependence of T-lymphocyte subpopulations and lymphocyte reactivityJ J Reiter, G Ehrlich, U BickerExperimentelle Pathologie|January 1, 1977
Experimental investigations on increased resistance to infections with Candida albicans and Staphylococcus aureus Smith by 4-imino-1,4-diazobicyclo-(3.1.0)-hexane-2-on BM 06.002 (prop. INN imexon) in miceA E Ziegler, U Bicker, G HeboldOsterreichische Zeitschrift Fur Onkologie. Austrian Journal of Oncology|January 1, 1977
Immunestimulation by 4-imino-1,3-diazabicyclo(3.1.0.)-hexan-2-on (BM 06.002)C M Cerni, W A Rella, U BickerJournal of Immunopharmacology|January 1, 1985
The influence on the formation of unstable haemoglobin by the immunomodulating 2-cyanaziridines azimexone and BM 41.332 in miceB Isert, K Mengel, U Bicker, et al.Experimentelle Pathologie|January 1, 1978
Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(1)]-propane BM 12 531U Bicker, G Hebold, A E Ziegler, et al.Journal of Immunopharmacology|January 1, 1984
Comparative investigations of various immunoregulatory substances in the delayed type hypersensitivity test of the mouseU Bicker, K D Friedberg, B Isert, et al.Experientia|October 15, 1979
Reduction of acute toxicity of cyclophosphamide and X-rays by the new immunomodulating compound BM 12.531U Bicker, K D Friedberg, G Hebold, et al.Journal of Immunopharmacology|January 1, 1986
Suppression of spontaneous insulin-dependent diabetes in BB rats by administration of ciamexoneU Kiesel, K Maruta, U Treichel, et al.Experimental Pathology|January 1, 1981
Influence of the immunomodulating compound BM 12.531 (azimexone) on radioresistance and granulopoietic colony forming units in miceW D Gassel, H Laukel, R Braun, et al.Osterreichische Zeitschrift Fur Onkologie. Austrian Journal of Oncology|January 1, 1977
Immunestimulation in cancer patients by a new synthetic compound: BM 06 002M Micksche, E M Kokoschka, O Kokron, et al.Pageof 4